Our study highlights the correlation of ERCC5 polymorphisms with various clinicopathological factors, overall survival rates with different survival functions, linkage disequilibrium analysis, and therapeutic outcomes of different chemotherapeutic drugs among breast cancer patients. Here, ERCC5 is linked to breast carcinoma.